Fenretinide intravenous - CerRx

Drug Profile

Fenretinide intravenous - CerRx

Alternative Names: 4-HPR – CerRx

Latest Information Update: 21 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ortho-McNeil Pharmaceutical
  • Developer CerRx
  • Class Antineoplastics; Chemopreventatives; Retinoids; Small molecules
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Peripheral T-cell lymphoma; Solid tumours
  • Preclinical Lymphoma

Most Recent Events

  • 21 Jul 2016 Preclinical trials in Lymphoma (Combination therapy, In adults) in USA (IV)
  • 21 Jul 2016 Preclinical trials in Solid tumours (Combination therapy) in USA (IV)
  • 19 Apr 2016 Phase-I clinical trials in Solid tumours (In adolescents, In children, In infants, In neonates) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top